Tokio Marine Asset Management Co. Ltd. Buys 200 Shares of Solventum Co. (NYSE:SOLV)

Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Solventum Co. (NYSE:SOLV) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,966 shares of the company’s stock after acquiring an additional 200 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Solventum were worth $346,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in SOLV. Davis Selected Advisers bought a new stake in Solventum during the second quarter worth approximately $273,070,000. Nuance Investments LLC acquired a new stake in shares of Solventum in the second quarter worth $115,829,000. Newport Trust Company LLC bought a new stake in shares of Solventum during the 2nd quarter worth $98,976,000. Baupost Group LLC MA acquired a new position in Solventum in the 2nd quarter valued at $96,242,000. Finally, Magnetar Financial LLC raised its holdings in Solventum by 2,880.8% in the 2nd quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock worth $78,813,000 after acquiring an additional 1,440,410 shares during the period.

Solventum Stock Down 0.6 %

Shares of SOLV stock opened at $67.48 on Friday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock has a fifty day moving average price of $70.54 and a 200 day moving average price of $62.22.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating on the stock. Wells Fargo & Company dropped their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. Wolfe Research initiated coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. Finally, Piper Sandler boosted their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.